Compare Lockheed Martin Corporation (LMT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs TransMedics Group Inc — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Lockheed Martin Corporation is far larger — about 42.8× TransMedics Group Inc's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and TransMedics Group Inc for 24 Days on average.
| LMT | TMDX | |
|---|---|---|
Market Cap | $117.22B | $2.74B |
Volume | 1,101,121 | 949,331 |
Sector | Industrials | Health |
52-Week High | $676.70 | $150.42 |
52-Week Low | $439.19 | $61.99 |
Typical Hold Time | 86 Days | 24 Days |
Enterprise Value | $133.96B | $3.13B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $507.89, up 1.74% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed Q1 and Q4 2025 expectations, with revenue growth from $75.05B in 2025 to projected $77.0B in 2026. Recent news highlights AI integration and F-35 program developments, while analyst consensus remains strongly bullish with a $635.33 price target.
LMT offers stable defense sector exposure with 23 consecutive dividend increases and strong cash flow, but faces execution risks on fixed-price contracts and competitive pressures. The stock trades at reasonable valuations (P/E 18.73, P/S 1.53) with high institutional support, though technical weakness near support at $503 requires monitoring for sustained upward momentum.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
